Correlation between mild behavioral impairment and peripheral blood biomarkers in patients with mild cognitive impairment

轻度认知障碍患者轻度行为障碍与外周血生物标志物之间的相关性

阅读:1

Abstract

BACKGROUND: Mild behavioral impairment (MBI) refers to the neurobehavioral symptoms observed in older adults that may be potential risk factors for neurodegenerative diseases. While a significant number studies have explored the association between cerebrospinal fluid and MBI, only a few have examined the connection between plasma biomarkers and MBI. AIM: To examine the prevalence of MBI in healthy older adults (HOAs) and individuals with mild cognitive impairment (MCI), as well as the association between MBI and plasma biomarkers of Alzheimer's disease (AD). METHODS: We enrolled a total of 241 subjects, which included 136 HOAs and 105 MCIs, from the Yuhua District of Shijiazhuang City, Hebei Province, China. The MBI symptom checklist (MBI-C) was utilized for the assessment and diagnosis of MBI, and a score of MBI-C ≥ 6.5 was considered indicative of the condition. Fasting venous blood samples were collected from 70 patients, 32 HOAs and 38 MCIs, and levels of amyloid β-protein (Aβ) 40, Aβ42, and hyperphosphorylated tau (p-Tau217) in these samples were measured using an enzyme-linked immunosorbent assay. RESULTS: The prevalence of MBI in the HOAs and MCI groups was 4.4% and 15.3%, respectively (χ (2) = 7.262, P = 0.007), with particularly notable decreases in motivation and increases in impulse dyscontrol (the highest detection rate) and social inappropriateness (P < 0.05). The total MBI score correlated with Aβ42 and p-Tau217 (r = -0.385, P = 0.019; r = -0.330, P = 0.041), but not with Aβ40 or the Aβ42/40 ratio. Among the subdomains, impulse dyscontrol was correlated with Aβ42 (r = -0.401, P = 0.025). CONCLUSION: Both MCI and HOAs have exhibited a higher prevalence of MBI, with changes in impulse control behavior being the most common. MBI not only presents as an independent risk factor for cognitive decline but is also linked with AD-related peripheral biomarkers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。